Sonoma pharmaceuticals announces 1-for-20 reverse split of outstanding common stock

Boulder, co / accesswire / august 28, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced the timing for a 1-for-20 reverse split of its outstanding common stock which will be effected on august 29, 2024 at 5:00 pm edt. sonoma common stock will begin trading on the nasdaq capital market on a 1-for-20 adjusted basis when the market opens on august 30, 2024.
SNOA Ratings Summary
SNOA Quant Ranking